Intratumoral Heterogeneity: Tools to Understand and Exploit Clone Wars in AML.
In this issue of Cancer Cell, de Boer et al. refine a set of acute myeloid leukemia (AML)-enriched plasma membrane markers that can be used to identify, prospectively isolate, and longitudinally track leukemic subclones within individual AML patients, correlating immunophenotypic profiles with specific mutational signatures, transcription, functional behavior, and therapeutic outcomes.
Medical Research Council (MR/M010392/1)
Medical Research Council (MR/R009708/1)